10.50am EDT10:50
The UK health secretary, Sajid Javid, is facing legal action over the Immensa testing fiasco, in which about 43,000 people have been given false negative Covid results since September.
The Good Law Project, led by Jo Maugham QC, has sent a pre-action letter to Javid, seeking answers over the scandal and demanding to terminate Immensa’s contracts immediately, compensate the individuals affected and take action to properly regulate private testing firms.
Immensa was founded in May 2020 by Andrea Riposati, a former management consultant and owner of a DNA testing company. Three months later, the Department of Health bypassed the normal competitive procedures and awarded it a £119m PCR testing contract. Immensa was subsequently given a further £50m testing contract in August 2021.
Since the scandal broke it has emerged that Immensa was not fully accredited with the UK Accreditation Service. It was already the subject of an investigation into its sister company, Dante Labs, by the Competition and Markets Authority into its travel tests. Riposati is also the founder of Dante Labs.
Downing Street has denied claims that the false Covid test results from the Wolverhampton lab were to blame for a sharp rise in cases in south-west England, saying the region may have been catching up with the rest of the country.
Read more of Rowena’s report here:
Updated
at 11.20am EDT
9.43am EDT09:43
After Covid success, what next for mRNA vaccines?
It is one of the most remarkable success stories of the pandemic: the unproven technology that delivered the Moderna and Pfizer/BioNTech vaccines in record time, helping to turn the tide on Covid-19.
The vaccines are based on mRNA, the molecule that instructs our cells to make specific proteins. By injecting synthetic mRNA, our cells are turned into on-demand vaccine factories, pumping out any protein we want our immune system to learn to recognise and destroy.
Pre-pandemic, the technology was viewed with scepticism – a clever concept, but not guaranteed to deliver. Now there is growing confidence that mRNA vaccines could have far-reaching applications in tackling diseases from flu to malaria.